» Articles » PMID: 23628045

[Clinical Significance of Helicobacter Pylori in Children with Idiopathic Thrombocytopenic Purpura]

Overview
Specialty Hematology
Date 2013 May 1
PMID 23628045
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

This study was aimed to investigate the clinic significance of helicobacter pylori (HP) in children with idiopathic thrombocytopenic purpura (ITP). The infection of HP in 92 ITP children was determined by (13) C-Urea Breath Test, the same test was also performed on 66 healthy children. The 68 children infected with HP were randomly divided into 2 groups: single drug group treated only with corticosteroid and; combined drug group treated with corticosteroid and anti-helicobacter pylori treatment. The results showed that 68 patients infected with HP were found in 92 ITP children (74.7%), 26 patients infected with HP were observed in 66 healthy children (39.4%), which was lower than that in ITP children (74.7%, P < 0.05). After anti-helicobacter pylori therapy, the total effective rate and cure rate of ITP patients increased respectively from 73.5% to 94.1%, and the total recurrence rate (17.0%) was much lower than single drug group (47.1%, P < 0.05). Otherwise, after therapy the platelet count in both two groups increased continuously, and at the same time point, the platelet count in anti-helicobacter pylori group was higher than that in the single drug group (P < 0.05). It is concluded that the ITP children have a higher infection rate of HP, which may be involved in the pathogenesis of ITP. Anti-helicobacter pylori therapy would help to improve the therapeutic efficacy and reduce the recurrence of ITP children.

Citing Articles

Sequential eradication of Helicobacter pylori as a treatment for immune thrombocytopenia in patients with moderate thrombocytopenia: a multicenter prospective randomized phase 3 study.

Han B, Kim H, Yhim H, Oh D, Bae S, Shin H Ann Hematol. 2022; 101(7):1435-1445.

PMID: 35643952 DOI: 10.1007/s00277-022-04782-2.


High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura.

Takase K, Nagai H, Kadono M, Yoshioka T, Yoshio N, Hirabayashi Y Int J Hematol. 2020; 111(3):388-395.

PMID: 31897888 DOI: 10.1007/s12185-019-02808-6.


Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials.

Kim B, Kim H, Jang H, Kim J Gastroenterol Res Pract. 2018; 2018:6090878.

PMID: 30402091 PMC: 6198559. DOI: 10.1155/2018/6090878.